Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 164 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

 		Non-segmental Vitiligo Phase2 Australia
United States 		NCT07431177

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

 		Huntington Disease Phase3 United States NCT07326709

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

 		Geographic Atrophy Secondary to Age-related Macular Degeneration Phase2 United States NCT07441642

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

 		Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis South Korea NCT07243782

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

 		Metastatic Prostate Cancer China NCT07290270

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

 		Relapsing Multiple Sclerosis Germany NCT05344469

Remibrutinib in Real-world Clinical Practice - a US Sub-study

 		Chronic Spontaneous Urticaria United States NCT07358780

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

 		Chronic Spontaneous Urticaria United States NCT07408219

Remibrutinib in Real-world Clinical Practice

 		Chronic Spontaneous Urticaria United States NCT07358364

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

 		Breast Cancer Russia NCT06905301